NasdaqGM:MIRMBiotechs
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Health Canada’s LIVMARLI Approval And Recent Share Price Momentum
Mirum Pharmaceuticals (MIRM) shares are in focus after Health Canada authorized LIVMARLI for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis, expanding the drug’s reach in a rare pediatric liver disease.
See our latest analysis for Mirum Pharmaceuticals.
The Health Canada decision comes after a strong run in the share price, with Mirum’s 30 day share price return of 16.56% and 90 day share price return of 42.57% contributing to a very large 3 year total...